Half Of 1st Approved Generics Do Not Launch Due To Part D Formulary Obstacles, AAM Says

Medicare Part D program should place generics on tiers separate from brand drugs and create a dedicated tier for specialty generics and biosimilars, AAM advocates in white paper.

Formulary
AAM Advocates Speciality Formularly Tier To Differentiate Generics And Biosimilars

The Association for Accessible Medicines has gathered new data to bolster its argument that Medicare Part D plans should place generics on different formulary tiers than higher-priced brand drugs. It cites recent findings that fewer than half of first generics approved by the US Food and Drug Administration since 2016 are commercially available and of these, only about half were included on Part D formularies.

AAM released a white paper, "Access Denied: Why New Generics Are Not Reaching America's Seniors," on 23 September. It...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Generics

More from Biosimilars & Generics